Manus provides an industrial biotechnology platform that engineers microbial cell factories to produce sustainable, chemically identical bioalternatives to petrochemical, agricultural, or animal‑derived ingredients. By integrating AI‑driven strain design, precision fermentation, and end‑to‑end manufacturing services, Manus enables ingredient, flavor, fragrance, and chemical producers to access high‑performance replacements with lower cost, reliable supply, and reduced environmental impact.
Funding
Funding not disclosed
Founders
Product
Problem
Many essential food, beverage, fragrance, material, and industrial chemicals are sourced from petrochemical processes, agricultural extraction, or animal husbandry, leading to volatile supply chains, high environmental impact, and limited scalability.
Solution
Manus provides a full‑scale industrial biotechnology platform that engineers microbial cell factories to produce chemically identical “bioalternatives” to these conventional molecules. By integrating cell‑factory design, metabolic and enzyme engineering, and precision fermentation in its Boston and Augusta BioFacilities, Manus can develop, optimize, and manufacture complex ingredients at commercial volumes. The end‑to‑end BioOptimization Cycle™ accelerates strain development, reduces time‑to‑market, and ensures consistent, low‑cost supply while lowering resource use and emissions. Customers can access these bioalternatives through tailored BioAccelerator or BioManufacturing programs, receiving support from discovery through pilot and large‑scale production.
Target Audience
Primary customers are ingredient manufacturers, flavor and fragrance companies, and industrial chemical producers seeking sustainable, high‑performance replacements for plant‑derived, fossil‑based, or animal‑derived inputs.
Features
- Proprietary “universal chassis” microbes engineered for high‑yield production of over 150,000 complex molecules
- BioOptimization Cycle™ combining AI‑driven protein design, metabolic pathway engineering, and multivariate omics for rapid strain optimization
- State‑of‑the‑art precision‑fermentation facilities (250 mL to 600 kL) enabling pilot to full‑scale manufacturing
- Integrated end‑to‑end services: cell‑factory design, enzyme engineering, bioprocess development, and techno‑economic analysis
- Flexible partnership models (BioAccelerator for end‑to‑end development, BioManufacturing for scale‑up) and stand‑alone services for specific stages
- Proven commercial bioalternatives such as stevia Reb M, nootkatone, and valencene with >1000× productivity improvement over natural extraction